The first monotherapy for leukemia received FDA approval

Share This Post

The US FDA has approved gilteritinib Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or refractory acute myeloid leukemia ( AML ).

When used with gilteritinib , it also awards companion diagnostic genetic testing technology. The LeukoStrat CDx FLT3 mutation detection method developed by Invivoscribe Technologies , Inc. is used to detect FLT3 mutations in AML patients .

“About 25 % -30 % of AML patients with FLT3 mutated genes, ” FDA Drug Administration Center for FDA director of the Oncology and Hematology and Oncology Center product acting director Richard Pazdur , MD, and Research, said in a statement. These mutations are particularly associated with cancer aggressiveness and a higher risk of recurrence. “

Pazdur added that gilteritinib is the first approved drug to be used as a monotherapy in AML patient populations.

FLT3 is the most frequently mutated gene identified in AML ,and FLT3 internal tandem repeat mutations are associated with high relapse rates, short remissions, and poor survival outcomes. Gilteritinib is a highly selective FLT3 tyrosine kinase inhibitor that has been shown to have activity against FLT3 ITD mutations, and also inhibits FLT3 D835 mutations that can confer clinical resistance to other FLT3 inhibitors .

The 252 patients enrolled in the early phase 1/2 trial showed that 49 % of patients with relapsed or refractory AML and FLT3 mutations responded to gilteritinib . The median survival of these participants was more than 7 months. Only 12 % of patients without FLT3 mutations responded to gilteritinib , providing evidence that it can be used as a selective inhibitor of mutant FLT3 .

The approval was based on data from the ADMIRAL study, a randomized phase 3 trial in which 138 adult patients with FLT3- positive relapsed / refractory AML received 120 mg of oral gefitinib daily . In this group, 21 % of patients achieved complete remission or complete remission with partial hematological recovery. The ADMIRAL trial itself is still in progress, and detailed response and overall survival data are expected to be published next year.

https://www.medscape.com/viewarticle/905713

For details on leukemia treatment and second opinion, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy